ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 399

Nausea and Vomiting During Pregnancy and Spontaneous Abortion In Women With Rheumatoid Arthritis

Balambal Bharti1, Diana L. Johnson2 and Christina D. Chambers3, 1Pediatrics, University of California San Diego, La Jolla, CA, 2University of California San Diego Department of Pediatrics, La Jolla, CA, 3Pediatrics, University of California, San Diego, La Jolla, CA

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: pregnancy and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects I: Comorbidities in Rheumatoid Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Nausea and Vomiting during Pregnancy (NVP) has been associated with a decreased risk for spontaneous abortion (SAB). However, the Th1/Th2 imbalance that occurs in pregnancy and is accentuated in women with NVP has not been studied in women with autoimmune diseases (AI) with respect to risk for SAB.

Methods: As part of the ongoing Organization of Teratology Information Specialists Autoimmune Diseases in Pregnancy Project, pregnant women were surveyed regarding 1st trimester vomiting using the Pregnancy Unique Quantification of Emesis (PUQE) questionnaire. Other characteristics assessed included maternal demographics, lifestyle factors and health status, AI status, current pregnancy related characteristics, pregnancy planning, previous pregnancy loss, and outcome of the current pregnancy.  The severity of NVP was compared using the mean PUQE scores as well as categories of NVP. Cox proportional hazards regression models were constructed to estimate the adjusted hazard ratios for SAB in those with and without NVP. Separate models were constructed for women with and without AI. 

Results: Data were available for 182 women with AI (n = 92) and without AI (n = 90). The mean age of the women at delivery was 33±5 years, with enrollment in the study taking place at an average gestational age of 9±3 weeks. The prevalence of NVP in the entire sample was 65%, with a mean PUQE score of 4.91±1.96. The overall crude rate of SAB was 11%; the rate in women with AI was 13% compared to 9% in those without AI. Women with AI had lower PUQE scores as compared to those without AI, although the difference was not statistically significant (4.7 vs. 5.1; p=0.14). The crude rate of SAB among those with NVP was 9% compared to 16% among those without NVP.  The adjusted hazard ratio for SAB among women who had NVP compared to those who did not was 0.61 (95% CI, 0.23-1.62).  The adjusted hazard ratios for SAB in women with NVP compared to those without were similar and close to 1 both in women with and without AI (95% CIs, 0.19-2.02 and 0.08-1.47, respectively).

Conclusion:  The prevalence of NVP in this cohort of pregnant women with and without AI is comparable to the general population (65% compared to 60-90% in the general population).  Women with NVP had a lower risk of SAB compared to those without NVP. The association between NVP and SAB did not differ appreciably between women with and without AI.


Disclosure:

B. Bharti,
None;

D. L. Johnson,

Abbott Laboratories,

2,

Amgen,

2,

UCB,

2,

Roche Genentech,

2,

Sanofi-Aventis Pharmaceutical,

2,

Bristol-Myers Squibb,

2,

Sandoz,

2,

Teva Pharmaceuticals,

2,

CSL,

2,

Apotex,

2,

Barr Laboratories, Inc.,

2,

Novartis Pharmaceutical Corporation,

2,

GSK,

2;

C. D. Chambers,

Abbott Laboratories,

2,

Amgen,

2,

UCB,

2,

Roche Genentech,

2,

Sanofi-Aventis Pharmaceutical,

2,

Bristol-Myers Squibb,

2,

Sandoz,

2,

Teva Pharmaceuticals,

2,

Parr ,

2,

Apotex,

2,

Barr Laboratories, Inc.,

2,

CSL,

2,

GSK,

2,

Novartis Pharmaceutical Corporation,

2.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/nausea-and-vomiting-during-pregnancy-and-spontaneous-abortion-in-women-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology